Novo NordiskSee all their emails

Novo’s investigational CagriSema, a GLP-1 and amylin analogue, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology

A real announcement email from Novo Nordisk. Captured November 14, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Novo’s investigational CagriSema, a GLP-1 and amylin analogue, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology email from Novo Nordisk screenshot

Captured Announcement

Novo Nordisk announces clinical trial results from REDEFINE 9 showing ~21% weight loss with lower doses of investigational CagriSema.

Traditional press release layout featuring a top logo, bulleted highlights, detailed clinical trial narrative, statistical tables, and media contact info.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.